SCHEMBL74878

SCHEMBL74878

COC(=O)Cc1cccc(F)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.55
GAA P10253 2/20 0.50
ALDH1A1 P00352 1/20 0.50
GFER P55789 1/20 0.50
HSP90AB1 P08238 1/20 0.50
MRGPRX4 Q96LA9 1/20 0.48
MAOB P27338 2/20 0.48
CYP4F2 P78329 1/20 0.47
CYP4A11 Q02928 1/20 0.47
TAAR1 Q96RJ0 1/20 0.47
MAPT P10636 1/20 0.47
HPGD P15428 1/20 0.47
TSHR P16473 1/20 0.47
RAB9A P51151 2/20 0.46
IDO1 P14902 1/20 0.46
AGXT P21549 1/20 0.46
PDK2 Q15119 1/20 0.46
MAPK8 P45983 1/20 0.46
KDM4E B2RXH2 1/20 0.46
STAT1 P42224 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30692683 1.00 SLC7A5 (0.55) SLC7A5GAAALDH1A1GFERHSP90AB1
SCHEMBL13237150 0.88 VNN1 (0.47) SLC7A5GAAMRGPRX4MAOBTAAR1
SCHEMBL12400239 0.87 SLC7A5 (0.68) SLC7A5GAAALDH1A1GFERHSP90AB1
SCHEMBL18198072 0.86 SRC (0.51) ALDH1A1CYP4F2CYP4A11HPGDMEN1
SCHEMBL901672 0.83 TAAR1 (0.53) MRGPRX4MAOBTAAR1MAPT
SCHEMBL7643126 0.83 CYP2D6 (0.47) GAAMRGPRX4MAOBTAAR1RAB9A
SCHEMBL2485584 0.83 MAOB (0.58) MAOBMAPTRAB9ANPC1
SCHEMBL1132657 0.82 SYK (0.49) SLC7A5GAAALDH1A1GFERHSP90AB1
SCHEMBL10291819 0.82 SLC7A5 (0.55) SLC7A5GAAALDH1A1GFERHSP90AB1
SCHEMBL4394735 0.81 SLC7A5 (0.62) SLC7A5GAAALDH1A1GFERHSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4721737-A1 USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES Scinnohub Pharmaceutical Co., Ltd. (CN) 2026-04-08 EP disclosed
US-20260001886-A1 ENPP1 INHIBITORS I RE VENTURES I LLC (US) 2026-01-01 US disclosed
WO-2025233863-A1 ENPP1 INHIBITORS RE VENTURES I, LLC (US) 2025-11-13 WO disclosed
US-20250145635-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) 2025-05-08 US disclosed
EP-4548937-A1 ANTIBODY-DRUG COMPLEX Eisai R&D Management Co., Ltd. (JP) 2025-05-07 EP disclosed
US-20240424111-A1 Degrader Compounds and Uses Thereof CALICO LIFE SCIENCES LLC (US) 2024-12-26 US disclosed
EP-4455136-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE Scinnohub Pharmaceutical Co., Ltd. (CN) 2024-10-30 EP disclosed
CN-118702710-A Method for synthesizing organoboron compound by visible light catalysis 常州大学 2024-09-27 CN disclosed
CN-118574832-A Tri-fused ring compound, preparation, pharmaceutical composition and application thereof 上海奕拓医药科技有限责任公司 2024-08-30 CN disclosed
CN-118047755-A Synthesis method of lebol Lei Sheng 四川奥邦古得药业有限公司 2024-05-17 CN disclosed
EP-1286967-A1 CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LTD. (GB) 2003-03-05 EP disclosed
WO-2001087838-A1 CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LIMITED (GB) 2001-11-22 WO disclosed
US-5321021-A Tricyclic pyridine derivatives HOFFMANN-LA ROCHE INC. (US) 1994-06-14 US disclosed
US-5294635-A Heterocyclic compounds as aldose reductase inhibitors PFIZER, INC. (US) 1994-03-15 US disclosed
EP-0530198-A1 HETEROCYCLIC COMPOUNDS AS ALDOSE REDUCTASE INHIBITORS PFIZER INC. (US) 1993-03-10 EP disclosed
WO-1991015491-A1 HETEROCYCLIC COMPOUNDS AS ALDOSE REDUCTASE INHIBITORS PFIZER INC. (US) 1991-10-17 WO disclosed
US-5039672-A Administering enzyme inhibitors to control diabetes PFIZER INC. (US) 1991-08-13 US disclosed
US-5036066-A Muscle relaxants, anxiolytic agents, anticonvulsants HOFFMANN-LA ROCHE INC. (US) 1991-07-30 US disclosed
US-4889848-A 4-OXO-4H-BENZO(A)QUINOLIZINES; MUSCLE RELAXANTS; SEDATIVES; ANTICONVULSANTS; ANXIOLYTIC AGENTS HOFFMANN-LA ROCHE INC. (US) 1989-12-26 US disclosed
US-4735940-A Tricyclic pyridine derivatives and pharmaceutical compositions HOFFMANN-LA ROCHE INC. (US) 1988-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145635-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE BCL9, USP9X, BCL9L SLC7A5 4410/4885GAA 380/4885ALDH1A1 2611/4885
US-20260001886-A1 ENPP1 INHIBITORS I ENPP1, ENPP2, ENPP3 SLC7A5 2491/4885GAA 1457/4885ALDH1A1 2998/4885
US-20240424111-A1 Degrader Compounds and Uses Thereof PTPN1, PTPN2, PTPN5 SLC7A5 3722/4885GAA 167/4885ALDH1A1 2830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.